Why Credit Suisse Sees More Upside in Top Steel Stocks
Credit Suisse has updated its view on U.S. steel companies and where those companies stand to go from here.
All Work
Chris Lange
How Ionis Pharma Beat a Biotech Giant
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Nike Whiffs on the Top Line Despite Solid Earnings
Nike reported mixed fiscal third-quarter financial results after the markets closed on Tuesday.
Five Below Sinks Despite Earnings Beat
Five Below released a better-than-expected fiscal fourth-quarter earnings report after the markets closed on Tuesday.
3 Analysts Take Positive View on Apple, All for Different Reasons
24/7 Wall St. has come across a few recent analyst calls that all take a positive perspective on the iPhone giant for a few different reasons.
Vivint Solar Secures $200 Million Loan
Vivint Solar announced on Tuesday that it has closed a $200 million loan, just in the past week.
What to Expect From Five Below Earnings
Five Below is set to report its fiscal fourth-quarter financial results after the markets close on Tuesday.
Akorn Back on Track to Restate Results
Akorn reported its preliminary 2015 financial results before the markets opened on Tuesday and issued guidance for the 2016 full year.
Mattress Firm Sinks on Missed Earnings
Mattress Firm reported disappointing fiscal fourth-quarter financial results after the markets closed on Monday.
What to Look for in Nike Earnings
Nike is scheduled to release its fiscal third-quarter financial results after the markets close on Tuesday.
Moleculin Gears Up for IPO
Moleculin Biotech plans to list up to 2 million shares at an estimated $5.50 apiece in an IPO valued at up to $11 million.
Why Key Analyst Sees Major Steel Losing Momentum
While steel prices in the United States may see some near-term upside, one key analyst fears that momentum may run out of steam into summer.
Why Tesla Shares Could Rise Another $100
Argus expects Tesla to meet or exceed its production targets and to achieve positive cash flow in the first quarter of 2016.
Why Investors Still Like Celator Pharma Despite a Loss
Celator Pharmaceuticals reported its fourth-quarter financial results before the markets opened on Monday.
Advaxis Soars on Positive Survival Results
Advaxis made waves in the markets on Monday following the release of positive data from its most recent study.
What to Expect From Red Hat Earnings
Red Hat is scheduled to report its fiscal fourth-quarter financial results after the markets close on Tuesday.
Why JPMorgan Favors Nike Over Lululemon Now
JPMorgan has added athletic apparel and footwear giant Nike to its Analyst Focus list. At the same time, the firm removed Lululemon Atheletica from the list.
BioMarin Sinks Despite Meeting Primary Endpoint
BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.
Top 6 Earnings for the Week Ahead
24/7 Wall St. has put together a preview of Petrobras, Nike and some of the major companies reporting their quarterly results this coming week.
How Analysts View Valeant After an Earnings Catastrophe
Releasing preliminary results may have been ill-advised to release, as the impact was absolutely catastrophic to Valeant Pharmaceuticals stock.